ClinicalTrials.gg
RecruitingNCT07761676Updated Aug 12, 2026

The Cohort Construction Project of Peking University Third Hospital

An observational study in Multiple Chronic Conditions (Unspecified) and Large-scale Health Examination Cohort, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Peking University Third Hospital · Observational

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100,000
Ages
18 Years and older
Sex
All
01

Study summary

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

Read the detailed description

The construction of a health check-up follow-up cohort holds significant importance for public health research. Since its establishment in 2022, the Health Check-up Cohort of Peking University Third Hospital (PUTH) has been operational for three years. The cohort features comprehensive health check-up indicators, including physical examination, biochemical tests, cancer screening, and 13 other major categories of indicators. It is equipped with a robust data management system and collaborates with the Clinical Epidemiology Research Center and the biobank. A multidimensional database has been established, covering health check-up information, health questionnaires, and biological samples of the study subjects. The cohort adopts a bidirectional study design, with the retrospective part covering individuals who underwent health check-ups since 2011 and the prospective part continuously enrolling subjects since 2022. As of 2023, the PUTH Health Check-up Cohort has collected health check-up data from over 80,000 study subjects, with the longest follow-up duration reaching 12 years, forming a longitudinal health database with continuous follow-up.

The cohort construction project has achieved favorable research outcomes, with a total of 14 academic papers published, including 8 SCI papers, and two invention patents granted. In addition, the cohort has collaborated with clinical departments within the hospital and has previously received funding from both internal and external horizontal and vertical projects. The primary focus has been on conducting research on medical reference value ranges and disease prevention and control among the health check-up cohort population. Building on the solid foundation of previous work, the cohort study will continue to optimize and expand, aiming to align with international large-scale cohorts by constructing a health check-up cohort with a large sample size, long follow-up duration, and high follow-up density.

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

The construction of this health check-up cohort provides a solid data foundation for the prevention of chronic diseases, individualized health management, and research on healthy aging. Through long-term follow-up and large-scale data collection, it can reveal disease risk factors, develop early prediction models, and in combination with biomarkers and multi-omics technologies, it helps explore the relationship between biological age and health status, promoting the development of precision medicine and the optimization of public health policies.

02

Conditions studied

  • Multiple Chronic Conditions (Unspecified)
  • Large-scale Health Examination Cohort

Keywords

  • Health Management
  • Health Check-up
  • Cohort Study
03

In context

Multiple Chronic Conditions

89 studies on the registry are indexed under Multiple Chronic Conditions; 16 are open to participants now.

This study's planned enrollment of 100,000 is above the median of 160 across 16 observational studies indexed under Multiple Chronic Conditions.

Browse Multiple Chronic Conditions studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of individuals who voluntarily undergo health examinations at the Physical Examination Center of Peking University Third Hospital. Participants are recruited from group health examination populations (including employees from functional community units such as government agencies, schools, and enterprises) who have undergone at least two consecutive health examinations at the center. The study includes both retrospective and prospective participants, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years. Participants must be from group health examination populations who have undergone at least two consecutive health examinations at our Physical Examination Center.

Exclusion criteria

Exclusion Criteria:

  • Failure to provide . Incomplete data, including incomplete health examination self-administered questionnaires.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Functional Community Health Examination Cohort

    This cohort consists of employees from functional community units (such as government agencies, schools, and enterprises) who undergo regular health examinations at the Physical Examination Center of Peking University Third Hospital. The cohort integrates both retrospective and prospective data, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.

    Other: observational study

Interventions

  • Otherobservational study

    This is an observational study designed to investigate the mental health status and its influencing factors in the general physical examination population. No interventions are assigned to participants based on a protocol.

06

What researchers measure

Primary outcomes

  1. Systolic and Diastolic Blood Pressure

    Blood pressure will be measured using a standardized mercury sphygmomanometer after at least 5 minutes of rest in a seated position. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be recorded.

    Time frame: through study completion, an average of 3 year

  2. Fasting Lipid Profile (Total Cholesterol, Triglycerides, LDL-C, and HDL-C)

    Venous blood samples will be collected after at least 8 hours of overnight fasting. Serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.

    Time frame: through study completion, an average of 3 year

  3. Fasting Blood Glucose (FBG)

    Fasting venous blood samples will be collected after at least 8 hours of overnight fasting. Serum glucose levels will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.

    Time frame: through study completion, an average of 3 year

  4. Glycated Hemoglobin (HbA1c)

    Fasting venous blood samples will be collected and analyzed using high-performance liquid chromatography (HPLC) at the central laboratory of Peking University Third Hospital. HbA1c reflects average blood glucose levels over the previous 2 to 3 months.

    Time frame: through study completion, an average of 3 year

  5. Complete Blood Count (CBC)

    Fasting venous blood samples will be collected and analyzed using an automated hematology analyzer at the central laboratory of Peking University Third Hospital. Key parameters include white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT).

    Time frame: through study completion, an average of 3 year

  6. Routine Urinalysis

    Midstream clean-catch urine specimens will be collected and analyzed using an automated urine analyzer and microscopy at the central laboratory of Peking University Third Hospital. Key parameters include urine specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic examination of red blood cells, white blood cells, and casts.

    Time frame: through study completion, an average of 3 year

  7. Liver Function Panel

    Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), and albumin (ALB).

    Time frame: through study completion, an average of 3 year

  8. Renal Function Panel

    Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include serum creatinine (Cr), blood urea nitrogen (BUN), uric acid (UA), and estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI or MDRD equation.

    Time frame: through study completion, an average of 3 year

  9. Pulmonary Assessment

    Chest X-ray or low-dose chest CT will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of pulmonary abnormalities (e.g., nodules, infiltrates, or other clinically significant findings).

    Time frame: through study completion, an average of 3 year

  10. Abdominal Ultrasound Assessment

    Abdominal ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for evaluation of the liver, gallbladder, pancreas, spleen, and kidneys. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of abnormalities in each organ.

    Time frame: through study completion, an average of 3 year

  11. Carotid Artery Ultrasound Assessment

    Carotid artery ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for assessment of carotid intima-media thickness (CIMT) and plaque detection. CIMT will be measured in millimeters (mm). Plaque will be reported as present or absent. All findings will be interpreted by certified radiologists.

    Time frame: through study completion, an average of 3 year

Secondary outcomes

  1. BMI

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body mass index (BMI) will be calculated as weight in kilograms divided by height in meters squared (kg/m²).

    Time frame: through study completion, an average of 3 year

  2. Body Fat Percentage

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body fat percentage (BFP) will be reported as a percentage (%).

    Time frame: through study completion, an average of 3 year

  3. Visceral Fat Area

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Visceral fat area (VFA) will be reported in square centimeters (cm²).

    Time frame: through study completion, an average of 3 year

  4. Skeletal Muscle Mass

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Skeletal muscle mass (SMM) will be reported in kilograms (kg).

    Time frame: through study completion, an average of 3 year

  5. Handgrip Strength

    Physical fitness will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Handgrip strength will be measured using a handheld dynamometer and reported in kilograms (kg).

    Time frame: through study completion, an average of 3 year

  6. Back Strength

    Back strength will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a back dynamometer following standardized protocols. Results will be measured and reported in kilograms (kg).

    Time frame: through study completion, an average of 3 year

  7. Vertical Jump Height

    Vertical jump height will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a force platform or jump mat following standardized protocols. Results will be measured and reported in centimeters (cm).

    Time frame: through study completion, an average of 3 year

  8. Estimated VO₂max

    Cardiorespiratory function will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Estimated maximal oxygen uptake (VO₂max) will be calculated and reported in milliliters per kilogram per minute (ml/kg/min).

    Time frame: through study completion, an average of 3 year

Other outcomes

  1. Thyroid Function Panel

    Fasting venous blood samples will be collected and analyzed using an automated chemiluminescence immunoassay analyzer at the central laboratory of Peking University Third Hospital. Key parameters include thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4). Additional parameters (e.g., total T3, total T4, anti-thyroglobulin antibody \[TG-Ab\], and anti-thyroid peroxidase antibody \[TPO-Ab\]) may be measured as clinically indicated.

    Time frame: Measured at baseline and at each annual health examination visit

  2. Inflammatory Biomarker Panel

    Fasting venous blood samples will be collected and analyzed at the central laboratory of Peking University Third Hospital. The inflammatory biomarker panel includes high-sensitivity C-reactive protein (hsCRP) measured by immunoturbidimetry, and a panel of serum cytokines (including but not limited to IL-6, TNF-α, IL-10, and IL-17A) measured using a multiplex immunoassay system. Additional inflammatory markers such as white blood cell count (WBC) and ferritin will also be assessed. All measurements will be performed following standardized protocols.

    Time frame: Measured at baseline and at each annual health examination visit

07

Study locations

1 of 1 sites recruiting
  • Physical Examination Center, Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Recruiting
    • Peng Wang, MMed · Contactbysywp@126.com · +86 13601015655
    • Liyuan Tao, PhD · Contacttendytly@163.com · +86 13581552613
    • Peng Wang, MMed · Principal investigator
    • Liyuan Tao, PhD · Sub investigator
    • Ying Che, MS · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Aug 12, 2026
StartActual
Feb 21, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07761676
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Feb 21, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Liyuan Tao, PhD
Contact
tendytly@163.com
+86 13581552613
Honghai He, MPH
Contact
hehonghai2011@126.com
+86 15101049480
Peng Wang, MMed
study director · Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion